Ultragenyx Pharmaceutical Inc. reported on December 29, 2025, that their studies for setrusumab (UX143) in Osteogenesis Imperfecta did not achieve significant reductions in fracture rates, although improvements in bone mineral density were noted. The company will also implement significant expense reductions as they evaluate their operations.